The FDA-cleared AISight Dx system will enable fully digital workflows and AI-enabled insights across anatomic pathology labs and hospital partnerships.
Labcorp announced an expanded collaboration with PathAI to deploy AISight Dx, a US Food and Drug Administration (FDA)-cleared digital pathology platform, across its national network of anatomic pathology labs and hospital collaborations.
The cloud-based technology allows pathologists to view and manage slides digitally while using AI to support key steps in the diagnostic process. The platform integrates AI-powered image analysis, secure storage, and system connectivity to deliver faster turnaround times, greater efficiency, and improved collaboration.
“Labcorp is committed to building a modern, AI-powered infrastructure that sets a new standard for efficiency, collaboration, and innovation in pathology,” says Dr Marcia Eisenberg, chief scientific officer at Labcorp, in a release. “PathAI’s technology allows us to scale digital pathology nationwide and integrate AI insights into routine care—delivering faster, more consistent results for patients and providers.”
Enabling Fully Digital Workflows
The deployment will enable fully digital workflows for case management, slide review, collaboration, and annotation across Labcorp’s anatomic pathology operations. The company will also incorporate digital pathology workflows to support its precision medicine products.
AISight Dx is FDA-cleared for primary diagnosis in the US and CE-IVD marked for primary diagnosis in the European Economic Area, UK, and Switzerland.
“Labcorp’s leadership in diagnostics makes them an ideal partner in our mission to modernize pathology through software and AI,” says Dr Andy Beck, co-founder and CEO of PathAI, in a release. “The deployment of AISight Dx across Labcorp’s network brings high-quality, efficient digital pathology to a national scale.”
The expansion builds on Labcorp’s 2019 strategic investment in PathAI. The collaboration has since advanced to include AI-driven clinical trial support and validation of novel AI-pathology solutions.
Photo credit: Labcorp
